# US Chikungunya Vaccine Market > US Chikungunya Vaccine Market Research Report: By Product Technology (Live-Attenuated Virus Vaccines, Inactivated Viral Vaccine, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates, Others), By Age Group (Pediatric, Adult, Geriatric) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 10.32% - **2024:** $ 63 Million - **2025:** $ 69.5 Million - **2035:** $ 185.5 Million - **Key Players:** Sanofi (FR), GSK (GB), Merck (US), Pfizer (US), Bharat Biotech (IN), Takeda (JP), Novavax (US), Inovio Pharmaceuticals (US) **Report ID:** MRFR/Pharma/11905-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-chikungunya-vaccine-market-13430 --- ## Market Summary ## **US Chikungunya Vaccine Market Overview** **As per MRFR analysis, the US Chikungunya Vaccine Market Size was estimated at 56.7 (USD Million) in 2023. The US Chikungunya Vaccine Market Industry is expected to grow from 63(USD Million) in 2024 to 193 (USD Million) by 2035. The US Chikungunya Vaccine Market CAGR (growth rate) is expected to be around 10.714% during the forecast period (2025 - 2035).** ### **Key US Chikungunya Vaccine Market Trends Highlighted** The US Chikungunya Vaccine Market is witnessing a shift driven by increasing awareness and concern about vector-borne diseases. One of the key market drivers is the growing prevalence of Chikungunya cases, particularly in areas where Aedes mosquitoes thrive, such as southern states. This has prompted health authorities to prioritize research and development of vaccines, with several candidates undergoing clinical trials to establish their efficacy and safety. Moreover, government initiatives aimed at controlling mosquito populations and educating the public on prevention methods are fostering a conducive environment for vaccine development. Opportunities in the market are expanding as collaboration between public health organizations, pharmaceutical companies, and research institutions accelerates. The emphasis on innovative vaccine technologies, such as mRNA platforms, presents significant potential to create effective and rapid solutions against Chikungunya. Additionally, leveraging digital health technologies for disease monitoring and public health communication can enhance outreach and vaccine deployment strategies. In recent times, trends indicate a shift towards proactive disease management strategies, with an increased focus on vaccine accessibility, especially in underserved communities. Efforts to integrate [Chikungunya vaccine](../../../reports/chikungunya-vaccine-market-11066) education into broader public health programs are emerging, signifying a united front against the disease. Overall, these market trends point to a dynamic landscape, where advancements in science and cooperative strategies are positioned to strengthen the defense against Chikungunya in the US.  Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Chikungunya Vaccine Market Drivers** ### **Rising Incidence of Chikungunya Cases in the US** The US has witnessed several outbreaks of Chikungunya in recent years, with notable cases reported in states such as Florida and Texas. According to the Centers for Disease Control and Prevention (CDC), there were approximately 1,100 reported cases in the US between 2014 and 2019. This increase in reported cases has heightened the demand for effective preventive measures, including vaccines. As awareness of Chikungunya and its debilitating effects grows, public health initiatives and funding support research for vaccines. Entities like the National Institutes of Health (NIH) have supported vaccine development projects. This push for vaccine development is crucial as health authorities recognize the potential of Chikungunya as a public health threat in the region. Consequently, this increasing disease burden is expected to be a significant driver for the growth of the US Chikungunya Vaccine Market Industry. ### **Technological Advancements in Vaccine Development** Recent advancements in vaccine technology, including the utilization of mRNA and viral vector platforms, have accelerated development cycles and improved vaccine efficacy. The ability to rapidly prototype vaccines against emerging viruses like Chikungunya reflects the adaptability of Research and Development (R&D) efforts in the US. The Food and Drug Administration (FDA) has been proactive in fast-tracking innovative vaccine candidates, which has led to increased investments from pharmaceutical companies and start-ups. The US Chikungunya Vaccine Market Industry benefits from these innovations, as they enable quicker responses to viral outbreaks, thus addressing public health emergencies effectively. ### **Increased Government Funding for Infectious Disease Research** In light of the Covid-19 pandemic, the US government has significantly increased its funding for infectious disease research and vaccine development. The National Institutes of Health (NIH) allocated more than $42 billion for medical research in fiscal year 2022, with a portion specifically targeting vaccine and infectious disease initiatives. Such funding fosters partnerships between public institutions, private companies, and academic entities, focusing on vaccine research against viruses like Chikungunya. This robust financial backing is anticipated to enhance the pipeline of innovative vaccine candidates, thereby driving growth in the US Chikungunya Vaccine Market Industry. ## **US Chikungunya Vaccine Market Segment Insights** ### **Chikungunya Vaccine Market Product Technology Insights** The Product Technology segment of the US Chikungunya Vaccine Market is pivotal in shaping the future of immunization strategies against Chikungunya virus. This segment encompasses various innovative technologies such as Live-Attenuated Virus Vaccines, Inactivated Viral Vaccines, Recombinant Viral Vaccines, Chimeric-Alphavirus Candidates, and other developing modalities, each playing a crucial role in vaccine efficacy and safety. Live-Attenuated Virus Vaccines have shown promise in eliciting robust immune responses, which is essential in offering lasting protection while minimizing reactogenicity. Inactivated Viral Vaccines, known for their safety profile, allow for wider usage in populations sensitive to live vaccines, including pregnant women and immunocompromised individuals, thereby expanding the public health outreach capability. Recombinant Viral Vaccines represent a cutting-edge approach, utilizing genetically engineered viruses to elicit targeted immune responses, potentially leading to more effective vaccines with fewer side effects. The emergence of Chimeric-Alphavirus Candidates marks a significant advancement in vaccine technology by combining the effectiveness of alphaviruses while reducing virulence. Other modalities under exploration reflect the rapid evolution and innovation in the vaccine development process, driven by the need to address outbreaks in urban and rural populations. Growth in this market segment is largely dependent on increasing public awareness of Chikungunya, funding for Research and Development, and the imperative for efficient and accessible vaccination programs in the United States. The ongoing commitment to advancing vaccine technologies fuels the market, presenting ample opportunities for researchers and industry players to address the healthcare needs related to vector-borne diseases. Overall, the focus on enhancing product technology within the US Chikungunya Vaccine Market underscores the strategic importance of scientifically advanced and rigorously tested vaccines to combat emerging infectious diseases effectively. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Chikungunya Vaccine Market Age Group Insights** The Age Group segment of the US Chikungunya Vaccine Market is a critical area of focus given the varying susceptibility and disease impact across different age demographics. This market encompasses three primary groups: Pediatric, Adult, and Geriatric. The Pediatric segment plays a significant role as younger individuals are often more vulnerable to infectious diseases, making vaccines essential for prevention. Adults typically exhibit high vaccine acceptance due to increased awareness of Chikungunya’s potential impact on health and productivity, thus showcasing a robust demand within this age category. The Geriatric population is particularly significant, as older adults tend to have compromised immune systems and are at a higher risk for severe disease outcomes. Strategies to target each of these age groups are crucial, as their healthcare needs can differ markedly; hence, tailored vaccination programs could greatly improve overall effectiveness. The dynamics of the US population, with a rising elderly demographic, are expected to influence the demand for targeted vaccination solutions significantly. Understanding these market dynamics and trends is vital for optimizing vaccine delivery and ensuring better public health outcomes. ### **Chikungunya Vaccine Market Distribution Channel Insights** The US Chikungunya Vaccine Market is significantly influenced by its Distribution Channel segment, which plays a vital role in ensuring access and availability of vaccines. Hospital pharmacies often serve as a primary point for administering vaccines, ensuring high accessibility for patients under medical supervision, while retail pharmacies cater to a broader public, providing convenience and ease of access. This segment is becoming increasingly important as the US healthcare system aims to enhance vaccination rates, especially following outbreaks of Chikungunya. The 'Others' category encompasses various distribution networks that contribute to making the vaccine more widely available across different regions, catering to specific community needs. The trends in these channels indicate a growing shift towards integrated healthcare solutions, enhancing patient outreach and education about vaccine benefits. With more healthcare entities focusing on vaccination campaigns, the distribution channels face opportunities to innovate and expand their reach, thereby boosting the US Chikungunya Vaccine Market revenue. Moreover, the ongoing efforts by the US government and health organizations to promote immune health and disease prevention further underline the significance of efficient distribution strategies in combating infectious diseases like Chikungunya. ## **US Chikungunya Vaccine Market Key Players and Competitive Insights** The US Chikungunya Vaccine Market is witnessing significant competitive dynamics as various pharmaceutical and biotechnology firms endeavor to develop effective vaccines against the chikungunya virus, transmitted primarily by mosquitoes. With increasing awareness about the disease and its implications on public health, there has been a surge in research and development initiatives aimed at bringing promising vaccine candidates to fruition. The market's competitive landscape is characterized by collaborations, clinical trial advancements, and strategic partnerships that are aimed at targeting this infectious threat more effectively. Alongside regulatory approvals and market entry strategies, the competition is heavily influenced by the need for robust clinical evidence and the capacity to manufacture and distribute vaccines effectively within the United States. Vaxart has emerged as a key player in the US Chikungunya Vaccine Market, leveraging its innovative oral vaccine platform that offers distinct advantages over traditional intramuscular injection methods. The company focuses on the development of its vaccine candidates utilizing its proprietary technology, which enables them to present a unique approach to immunization delivery. Vaxart's strengths lie not only in its advanced research capabilities but also in its strong intellectual property position that allows for differentiation in the competitive landscape. Additionally, the company's commitment to addressing unmet medical needs in chikungunya vaccination has garnered attention from investors and stakeholders alike, highlighting its potential to make a significant impact in the market should clinical trials yield favorable results. Merck is another formidable contender in the US Chikungunya Vaccine Market, recognized for its long-standing expertise in vaccine development and a rich portfolio of successful products. The company has a strong market presence through established vaccination programs, which provides a solid operational backbone for entering new infectious disease markets, including chikungunya. Merck’s commitment to innovation is evident through its extensive research and development programs, often bolstered by collaborations and strategic alliances with academic institutions and other biotech companies. The company is known for its robust pipeline and has made several strategic acquisitions that enhance its capabilities in developing vaccines. With a focus on delivering quality healthcare solutions and addressing emerging health threats such as chikungunya, Merck is well-positioned to leverage its resources and experience in navigating the complexities of the US vaccine landscape. ### **Key Companies in the US Chikungunya Vaccine Market Include** ## **US Chikungunya Vaccine Market Industry Developments** The US Chikungunya Vaccine Market has seen notable developments recently, with several companies advancing their vaccine programs. For example, in September 2023, Moderna announced progress in its Chikungunya vaccine candidate after positive Phase 2 trial results, indicating significant immune responses. Merck is also actively exploring Chikungunya vaccines, leveraging its vaccine development expertise. Moreover, in August 2023, GSK expanded its vaccine research capabilities, focusing on vector-borne diseases, which includes Chikungunya. In terms of mergers and acquisitions, there have been no recent high-profile events directly related to major players like Pfizer or Johnson and Johnson in this specific market. The growth of these companies indicates an increasing market valuation due to heightened demand for effective vaccines. Over the past two to three years, regulatory submissions have accelerated, with the U.S. Food and Drug Administration emphasizing the importance of developing vaccines for emerging diseases like Chikungunya. This proactive approach reflects the US government's commitment to public health and epidemic preparedness, further stimulating interest and investment in the Chikungunya vaccine sector. ## **US Chikungunya Vaccine Market Segmentation Insights** ### **Chikungunya Vaccine Market Product Technology Outlook** ### **Chikungunya Vaccine Market Age Group Outlook** ### **Chikungunya Vaccine Market Distribution Channel Outlook** - Hospital Pharmacies - Retail Pharmacies - Others ## Market Drivers ### Global Travel and Trade Dynamics The dynamics of The chikungunya vaccine market significantly. As international travel increases, the risk of chikungunya transmission also rises, particularly in regions where the virus is endemic. Travelers returning to the US from affected areas may introduce the virus, leading to localized outbreaks. This potential for outbreaks may prompt health authorities to recommend vaccination for travelers, thereby increasing demand for chikungunya vaccines. Additionally, the interconnectedness of global trade may facilitate the distribution of vaccines, making them more accessible to populations at risk. Thus, the chikungunya vaccine market could see growth driven by the need for preventive measures in the context of global mobility. ### Advancements in Vaccine Technology Technological advancements in vaccine development are poised to enhance the chikungunya vaccine market. Innovations such as mRNA technology and viral vector platforms have shown promise in creating effective vaccines against various infectious diseases. These advancements may lead to the development of more effective and safer chikungunya vaccines, which could significantly boost public confidence in vaccination. Furthermore, the ability to produce vaccines more rapidly and efficiently could address the urgent need for immunization in response to outbreaks. As a result, the chikungunya vaccine market may see an influx of new products that leverage these technologies, potentially increasing market share and accessibility. ### Rising Incidence of Chikungunya Cases The chikungunya vaccine market is likely to experience growth due to the increasing incidence of chikungunya cases in the US. Reports indicate that the number of chikungunya infections has risen significantly, with thousands of cases reported annually. This surge in cases raises public awareness and concern, prompting health authorities to prioritize vaccine development and distribution. The Centers for Disease Control and Prevention (CDC) has noted that the disease can lead to severe joint pain and other debilitating symptoms, which further emphasizes the need for effective vaccination strategies. As the population becomes more aware of the risks associated with chikungunya, the demand for vaccines is expected to increase, thereby driving the chikungunya vaccine market forward. ### Increased Public Awareness and Education Public awareness campaigns regarding chikungunya and its potential health impacts are likely to drive the chikungunya vaccine market. As educational initiatives increase, more individuals are becoming informed about the disease, its transmission, and the benefits of vaccination. Health organizations are actively promoting the importance of vaccines in preventing chikungunya, which may lead to higher vaccination rates. This heightened awareness could translate into increased demand for vaccines, as individuals seek protection against the disease. Consequently, the chikungunya vaccine market may benefit from a more informed public that recognizes the value of immunization in safeguarding health. ### Government Support and Policy Initiatives Government support plays a crucial role in shaping the chikungunya vaccine market. Federal and state health agencies are increasingly recognizing the importance of vaccination in controlling vector-borne diseases. Initiatives aimed at funding research and development of chikungunya vaccines are being implemented, which may lead to increased investment in this area. For instance, the National Institutes of Health (NIH) has allocated substantial resources to support vaccine trials and studies. Such government backing not only facilitates the development of effective vaccines but also encourages private sector involvement, thereby expanding the chikungunya vaccine market. The collaboration between public and private entities is likely to enhance the overall efficacy and reach of vaccination programs. ## Future Outlook The [Chikungunya Vaccine Market](https://www.marketresearchfuture.com/reports/chikungunya-vaccine-market-11066) is projected to grow at a 10.32% CAGR from 2025 to 2035, driven by rising disease prevalence and increased public health initiatives. **New opportunities:** - Development of mobile vaccination units for remote areas - Partnerships with local health organizations for community outreach - Investment in digital health platforms for vaccine tracking and education By 2035, the chikungunya vaccine market is expected to achieve substantial growth and enhanced accessibility. ## Segment Insights ### By Product Technology: Live-Attenuated Virus Vaccines (Largest) vs. Recombinant Viral Vaccines (Fastest-Growing) In the US chikungunya vaccine market, Live-Attenuated Virus Vaccines hold the largest market share due to their proven efficacy and long-standing use in immunization programs. These vaccines are preferred for their ability to induce strong immune responses, leading to higher uptake rates. Conversely, Recombinant Viral Vaccines are gaining traction as a fast-growing segment, attributed to recent advancements in biotechnology and increasing investments in research and development. The diversity in vaccine technology offers healthcare providers and patients a range of options to combat chikungunya effectively. Growth trends within the product technology segment are driven by emerging research and clinical trials emphasizing the safety and efficacy of new vaccine candidates. Live-Attenuated Virus Vaccines continue to be the dominant choice among healthcare professionals, bolstered by extensive clinical data. However, the shift towards Recombinant Viral Vaccines is fueled by their adaptability and potential for rapid production. The need for effective preventative measures against chikungunya, especially among high-risk populations, is propelling investments in innovative technologies, thereby enhancing overall market dynamics. Live-Attenuated Virus Vaccines (Dominant) vs. Recombinant Viral Vaccines (Emerging) Live-Attenuated Virus Vaccines are characterized by their ability to replicate in the host, resulting in a robust and long-lasting immune response. This segment is widely trusted due to its historical success in other viral diseases, providing confidence among healthcare providers. In contrast, Recombinant Viral Vaccines represent an emerging approach, utilizing genetic engineering techniques to produce vaccines that can be rapidly developed and tailored to specific viral strains. This flexibility allows for quicker responses to outbreaks, making them increasingly relevant in the US chikungunya vaccine market. Both segments demonstrate unique advantages, but the increasing push towards innovation positions Recombinant Viral Vaccines as a compelling alternative in the face of evolving epidemiological challenges. ### By Age Group: Adult (Largest) vs. Pediatric (Fastest-Growing) In the US chikungunya vaccine market, the distribution of market share among age groups reveals that the adult segment holds the largest share, reflecting the higher prevalence of chikungunya among this demographic. Adults tend to exhibit greater exposure to the virus due to increased mobility and outdoor activities, which correlates with the demand for vaccination. Meanwhile, the pediatric segment, although smaller, is experiencing rapid growth, driven by rising awareness about infectious diseases and increasing vaccination campaigns targeting children. The growth trends for these segments are influenced by various factors. The adult age group benefits from ongoing public health initiatives focusing on disease prevention, leading to sustained interest in vaccinations. Conversely, the pediatric segment is gaining momentum as healthcare providers emphasize the importance of vaccinating younger populations. This is supported by increasing parental concern regarding children's health and heightened vigilance against mosquito-borne diseases, resulting in a robust market outlook for pediatric vaccines. Adult (Dominant) vs. Pediatric (Emerging) The adult segment is characterized by its dominant market position, attributed to a higher risk of chikungunya infection in older populations. Adults typically engage in activities that expose them to mosquito bites, which leads to a strong demand for vaccination options. On the other hand, the pediatric segment is emerging as a vital part of the market, particularly as healthcare authorities prioritize immunizing children against infectious diseases. This segment is expanding due to parents' increasing awareness about the risks associated with chikungunya and the importance of prevention. As healthcare providers push for more robust vaccination measures, interaction with pediatric patients will likely lead to innovative strategies to enhance vaccine uptake in this group. ### By Distribution Channel: Hospital Pharmacies (Largest) vs. Retail Pharmacies (Fastest-Growing) In the current landscape of the US chikungunya vaccine market, hospital pharmacies command a significant share, primarily due to their established infrastructure and trusted relationships with healthcare providers. Retail pharmacies, while having a smaller share compared to hospital pharmacies, are quickly gaining traction as they enhance accessibility to vaccines for the general public through various outreach programs. The growth trends in this segment are driven by several factors, including increasing awareness about chikungunya and its prevention, along with strategic efforts to integrate vaccination services in retail pharmacies. The convenience and immediate availability offered by retail pharmacies position them as a rapidly emerging segment, appealing especially to younger populations seeking efficient healthcare solutions. Hospital Pharmacies: Dominant vs. Retail Pharmacies: Emerging Hospital pharmacies play a dominant role in vaccine distribution, leveraging their connections with healthcare facilities to ensure high vaccine uptake. They are equipped to handle the complexities associated with vaccine storage and administration, making them the preferred choice for larger and more regulated environments. On the other hand, retail pharmacies are emerging as vital players in the US chikungunya vaccine market. Their ability to offer convenience and flexibility in vaccination services attracts a diverse customer base. Retail chains are increasingly focusing on improving customer experience through extended hours and walk-in appointments, which complements the healthcare system's overall vaccination efforts. ## Competitive Benchmarking The chikungunya vaccine market is currently characterized by a dynamic competitive landscape, driven by increasing awareness of vector-borne diseases and the need for effective preventive measures. Key players such as Sanofi (FR), GSK (GB), and Merck (US) are actively engaged in innovation and strategic partnerships to enhance their market presence. Sanofi (FR) has focused on developing a robust pipeline of vaccines, leveraging its extensive research capabilities, while GSK (GB) emphasizes collaboration with public health organizations to facilitate vaccine distribution. Merck (US) appears to be concentrating on expanding its manufacturing capabilities to meet anticipated demand, thereby shaping a competitive environment that is increasingly reliant on innovation and strategic alliances.In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of vaccine distribution. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This collective presence of key players fosters a competitive atmosphere where innovation and operational efficiency are paramount. In October GSK (GB) announced a strategic partnership with a leading biotechnology firm to enhance its chikungunya vaccine development efforts. This collaboration is expected to leverage advanced technologies, potentially accelerating the vaccine's time to market. Such strategic moves indicate GSK's commitment to maintaining a competitive edge through innovation and collaboration. In September Merck (US) unveiled plans to invest $200 million in expanding its vaccine manufacturing facilities in the U.S. This investment is likely to bolster Merck's production capacity, ensuring a steady supply of chikungunya vaccines. The strategic importance of this expansion lies in its potential to enhance Merck's market position by addressing supply chain challenges and meeting growing demand. In August Sanofi (FR) launched a new digital platform aimed at improving vaccine accessibility and education for healthcare providers. This initiative reflects a broader trend towards digitalization in the healthcare sector, suggesting that Sanofi is keen on enhancing its customer engagement and support services. Such digital strategies may play a crucial role in shaping the future of vaccine distribution and public health outreach. As of November current trends in the chikungunya vaccine market are increasingly defined by digital transformation, sustainability, and the integration of artificial intelligence in research and development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and enhancing product offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, underscoring the importance of agility and responsiveness in a rapidly changing market. ## Recent News & Developments The US Chikungunya Vaccine Market has seen notable developments recently, with several companies advancing their vaccine programs. For example, in September 2023, Moderna announced progress in its Chikungunya vaccine candidate after positive Phase 2 trial results, indicating significant immune responses. Merck is also actively exploring Chikungunya vaccines, leveraging its vaccine development expertise. Moreover, in August 2023, GSK expanded its vaccine research capabilities, focusing on vector-borne diseases, which includes Chikungunya. In terms of mergers and acquisitions, there have been no recent high-profile events directly related to major players like Pfizer or Johnson and Johnson in this specific market. The growth of these companies indicates an increasing market valuation due to heightened demand for effective vaccines. Over the past two to three years, regulatory submissions have accelerated, with the U.S. Food and Drug Administration emphasizing the importance of developing vaccines for emerging diseases like Chikungunya. This proactive approach reflects the US government's commitment to public health and epidemic preparedness, further stimulating interest and investment in the Chikungunya vaccine sector. ## Report Scope | MARKET SIZE 2024 | 63.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 69.5(USD Million) | | MARKET SIZE 2035 | 185.5(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.32% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Sanofi (FR), GSK (GB), Merck (US), Pfizer (US), Bharat Biotech (IN), Takeda (JP), Novavax (US), Inovio Pharmaceuticals (US) | | Segments Covered | Product Technology, Age Group, Distribution Channel | | Key Market Opportunities | Emerging technologies in vaccine development enhance efficacy and accessibility in the chikungunya vaccine market. | | Key Market Dynamics | Regulatory advancements and competitive innovations drive growth in the chikungunya vaccine market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US chikungunya vaccine market in 2024?** A: The market valuation was $63.0 Million in 2024. **Q: What is the projected market valuation for the US chikungunya vaccine market by 2035?** A: The projected valuation for 2035 is $185.5 Million. **Q: What is the expected CAGR for the US chikungunya vaccine market during the forecast period 2025 - 2035?** A: The expected CAGR is 10.32% during the forecast period 2025 - 2035. **Q: Which product technology segment had the highest valuation in 2024?** A: The Recombinant Viral Vaccines segment had the highest valuation at $20.0 Million in 2024. **Q: What is the valuation range for Inactivated Viral Vaccines in the US chikungunya vaccine market?** A: The valuation range for Inactivated Viral Vaccines is $15.0 Million to $45.0 Million. **Q: Which age group segment is projected to have the highest market valuation in 2035?** A: The Adult age group segment is projected to have the highest valuation, ranging from $30.0 Million to $90.0 Million. **Q: What distribution channel had the highest valuation in 2024?** A: The Retail Pharmacies distribution channel had the highest valuation at $30.6 Million in 2024. **Q: Which key players are leading the US chikungunya vaccine market?** A: Key players include Sanofi, GSK, Merck, Pfizer, Bharat Biotech, Takeda, Novavax, and Inovio Pharmaceuticals. **Q: What is the valuation range for the Geriatric age group segment in the US chikungunya vaccine market?** A: The valuation range for the Geriatric age group segment is $23.0 Million to $65.5 Million. **Q: What is the projected growth trend for the US chikungunya vaccine market from 2025 to 2035?** A: The market is expected to grow significantly, with a projected valuation of $185.5 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-chikungunya-vaccine-market-13430*